{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:46:56Z","timestamp":1792363616481,"version":"4.4.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canrad.2025.104774","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:33:13Z","timestamp":1763753593000},"page":"104774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radiotherapy guidelines for gliomas: 2025 update"],"prefix":"10.1016","volume":"29","author":[{"given":"Delphine","family":"Antoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mesny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"El Kabbaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vin","family":"Quintin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Feuvret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Biau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15_suppl.","key":"10.1016\/j.canrad.2025.104774_bib0520","doi-asserted-by":"crossref","first-page":"e13005","DOI":"10.1200\/jco.2015.33.15_suppl.e13005","article-title":"Patterns of care for 1602 patients with newly diagnosed glioblastoma","volume":"33","author":"Bauchet","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104774_bib0525","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuchi.2012.01.004","article-title":"French brain tumor database: general results on 40,000 cases, main current applications and future prospects","volume":"58","author":"Zouaoui","year":"2012","journal-title":"Neurochirurgie"},{"issue":"7","key":"10.1016\/j.canrad.2025.104774_bib0530","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: a \u201cstate of the science\u201d review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0535","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0540","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0545","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104774_bib0550","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0555","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2011.06.1992","article-title":"Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma","volume":"83","author":"Minniti","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0560","first-page":"221","article-title":"General guidelines for the management of older patients with cancer","volume":"14","author":"Balducci","year":"2000","journal-title":"Oncol (Williston Park)"},{"issue":"2","key":"10.1016\/j.canrad.2025.104774_bib0565","first-page":"132","article-title":"Management of cancer in the older aged person","volume":"1","author":"Balducci","year":"1994","journal-title":"Cancer Control"},{"key":"10.1016\/j.canrad.2025.104774_bib0570","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0167-8140(02)00078-6","article-title":"Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review","volume":"64","author":"Laperriere","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0575","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11060-007-9426-z","article-title":"Delay in radiotherapy shortens survival in patients with high grade glioma","volume":"85","author":"Irwin","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-011-0589-2","article-title":"Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?","volume":"105","author":"Lawrence","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0585","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11060-012-0883-7","article-title":"Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy","volume":"109","author":"No\u00ebl","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0590","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0595","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104774_bib0600","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(07)70384-4","article-title":"Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981\/CE.3","volume":"9","author":"Gorlia","year":"2008","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.canrad.2025.104774_bib0605","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs. maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.canrad.2025.104774_bib0610","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/neuonc\/noad119","article-title":"Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)","volume":"26","author":"Laprie","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0615","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijrobp.2010.04.033","article-title":"Effectiveness of radiotherapy for elderly patients with glioblastoma","volume":"81","author":"Scott","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib0620","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/neuonc\/nor005","article-title":"Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases","volume":"13","author":"Scott","year":"2011","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104774_bib0625","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104774_bib0630","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1200\/JCO.2011.34.8086","article-title":"Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an Anocef phase II trial","volume":"29","author":"P\u00e9rez-Larraya","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0635","series-title":"R\u00e9f\u00e9rentiel de l\u2019Anocef pour les gliomes de l\u2019adulte","author":"Duffau","year":"2012"},{"key":"10.1016\/j.canrad.2025.104774_bib0640","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.1991.396","article-title":"A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party","volume":"64","author":"Bleehen","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2025.104774_bib0645","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2002.20.6.1635","article-title":"Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy","volume":"20","author":"Chan","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0650","first-page":"279","article-title":"Combined modality approach to treatment of malignant gliomas \u2013 re-evaluation of RTOG 7401\/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group","volume":"6","author":"Nelson","year":"1988","journal-title":"NCI Monogr"},{"key":"10.1016\/j.canrad.2025.104774_bib0655","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.14694\/EdBook_AM.2014.34.e89","article-title":"Is current technology improving outcomes with radiation therapy for gliomas?","author":"Brada","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.canrad.2025.104774_bib0660","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ctrv.2012.05.008","article-title":"Optimal management of elderly patients with glioblastoma","volume":"39","author":"Laperriere","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2025.104774_bib0665","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.semradonc.2014.06.009","article-title":"Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas","volume":"24","author":"Fogh","year":"2014","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0670","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104774_bib0675","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-019-03152-9","article-title":"NRG brain tumor specialists consensus guidelines for glioblastoma contouring","volume":"143","author":"Kruser","year":"2019","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104774_bib0680","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2024.11.094","volume":"121","author":"Qiu","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib0685","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/j.wneu.2014.06.042","article-title":"Stereotactic radiosurgery for recurrent high-grade gliomas","volume":"82","author":"Sheehan","year":"2014","journal-title":"World Neurosurg"},{"key":"10.1016\/j.canrad.2025.104774_bib0690","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11060-013-1337-6","article-title":"The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline","volume":"118","author":"Ryu","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0695","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.canrad.2010.03.021","article-title":"[Systematic review of stereotactic radiotherapy for high-grade gliomas]","volume":"14","author":"Clavier","year":"2010","journal-title":"Cancer Radiother"},{"issue":"1","key":"10.1016\/j.canrad.2025.104774_bib0700","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104774_bib0705","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ijrobp.2024.01.013","article-title":"Prospective randomized phase 2 trial of hypofractionated stereotactic radiation therapy of 25\u00a0Gy in 5 fractions compared with 35\u00a0Gy in 5 fractions in the reirradiation of recurrent glioblastoma","volume":"119","author":"Chen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib0710","doi-asserted-by":"crossref","first-page":"110437","DOI":"10.1016\/j.radonc.2024.110437","article-title":"Re-irradiation treatment regimens for patients with recurrent glioma\u00a0\u2013\u00a0Evaluation of the optimal dose and best concurrent therapy","volume":"199","author":"Fleischmann","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0715","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1200\/JCO.2005.03.4157","article-title":"Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution","volume":"23","author":"Combs","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104774_bib0720","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2025.104774_bib0725","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","article-title":"A prospective phase II randomized trial of proton radiotherapy vs. intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma","volume":"23","author":"Brown","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.canrad.2025.104774_bib0730","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"40","author":"Mohile","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.canrad.2025.104774_bib0735","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0740","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1200\/JCO.2005.04.3414","article-title":"Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402","volume":"24","author":"Cairncross","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0745","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0750","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.2005.04.6078","volume":"24","author":"Van den Bent","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0755","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951","volume":"31","author":"Van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0760","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1078-0432.CCR-09-2902","article-title":"IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group","volume":"16","author":"Van den Bent","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.canrad.2025.104774_bib0765","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.02543","article-title":"Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors","volume":"40","author":"Lassman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0770","first-page":"1529","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104774_bib0775","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104774_bib0780","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.24.00049","article-title":"Survival outcomes associated with first-line procarbazine, CCNU, and vincristine or temozolomide in combination with radiotherapy in IDH-mutant 1p\/19q-codeleted grade 3 oligodendroglioma","volume":"43","author":"Kacimi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.canrad.2025.104774_bib0785","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"Van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.canrad.2025.104774_bib0790","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1158\/1078-0432.CCR-21-4283","article-title":"Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post hoc analysis of the EORTC randomized phase III CATNON Trial","volume":"28","author":"Tesileanu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2025.104774_bib0795","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11060-010-0264-z","article-title":"Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma","volume":"101","author":"Ducray","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0800","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11060-014-1443-0","article-title":"IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy","volume":"118","author":"Minniti","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0805","doi-asserted-by":"crossref","first-page":"110594","DOI":"10.1016\/j.radonc.2024.110594","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma","volume":"202","author":"Baumert","year":"2025","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104774_bib0810","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.prro.2022.05.004","article-title":"Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma: an ASTRO clinical practice guideline","volume":"12","author":"Halasz","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0815","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2005.05.067","article-title":"Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results","volume":"64","author":"Narayana","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib0820","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2009.08.029","article-title":"Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas","volume":"78","author":"Cho","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib0825","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11060-013-1278-0","article-title":"Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors","volume":"116","author":"Habets","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0830","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ijrobp.2006.10.032","article-title":"Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain?","volume":"67","author":"Hermanto","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2025.104774_bib0835","doi-asserted-by":"crossref","first-page":"e097810","DOI":"10.1136\/bmjopen-2024-097810","article-title":"APPROACH: Analysis of Proton versus Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health\u00a0\u2013\u00a0study protocol paper for a phase III multicentre, open-label randomised controlled trial","volume":"15","author":"Slevin","year":"2025","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.canrad.2025.104774_bib0840","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11060-020-03612-7","article-title":"The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update","volume":"150","author":"Ziu","year":"2020","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104774_bib0845","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0360-3016(96)00352-5","article-title":"A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844","volume":"36","author":"Karim","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.canrad.2025.104774_bib0850","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2002.09.126","article-title":"Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group\/Radiation Therapy Oncology Group\/Eastern Cooperative Oncology Group study","volume":"20","author":"Shaw","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9490","key":"10.1016\/j.canrad.2025.104774_bib0855","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial","volume":"366","author":"van den Bent","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.canrad.2025.104774_bib0860","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.canrad.2025.104774_bib0865","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0870","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial","volume":"366","author":"Van den Bent","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.canrad.2025.104774_bib0875","first-page":"CD009229","article-title":"Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas","volume":"1","author":"Dhawan","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.canrad.2025.104774_bib0880","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","article-title":"Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up","volume":"8","author":"Douw","year":"2009","journal-title":"Lancet Neurol"},{"issue":"06","key":"10.1016\/j.canrad.2025.104774_bib0885","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/WCO.0000000000000257","article-title":"Chemotherapy for low-grade glioma: when, for whom, which regimen?","volume":"28","author":"van den Bent","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"10.1016\/j.canrad.2025.104774_bib0890","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2025.104774_bib0895","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11060-014-1563-6","article-title":"Diagnostic challenges, management and outcomes of midline low-grade gliomas","volume":"120","author":"Waqar","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0900","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.2002.08.121","article-title":"Prognostic factors for survival in adult patients with cerebral low-grade glioma","volume":"20","author":"Pignatti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0905","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijrobp.2010.05.003","article-title":"Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51","volume":"81","author":"Daniels","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib0910","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/neuonc\/not080","article-title":"Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years","volume":"15","author":"Youland","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0915","first-page":"1336","article-title":"Clinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: results of 10 years survival","volume":"7","author":"Kaya","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.canrad.2025.104774_bib0920","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-012-0953-x","article-title":"Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system","volume":"110","author":"Figarella-Branger","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2025.104774_bib0925","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.neurol.2011.08.006","article-title":"Chemotherapy for diffuse low-grade gliomas in adults","volume":"167","author":"Ducray","year":"2011","journal-title":"Rev Neurol (Paris)"},{"issue":"14","key":"10.1016\/j.canrad.2025.104774_bib0930","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.canrad.2025.104774_bib0935","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.19.02983","article-title":"Comprehensive genomic analysis in NRG Oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma","volume":"38","author":"Bell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104774_bib0940","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S1470-2045(16)30305-9","article-title":"Health-related quality of life in patients with high-risk low-grade glioma (EORTC2203326033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Reijneveld","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16 Supplement","key":"10.1016\/j.canrad.2025.104774_bib0945","doi-asserted-by":"crossref","first-page":"PL02.005","DOI":"10.1212\/WNL.86.16_supplement.PL02.005","article-title":"CODEL(Alliance-N0577; EORTC-26081\/22086; NRG-1071; NCIC-CEC-2): phase III randomized study of RT vs. RT\u00feTMZ vs. TMZ for newly diagnosed 1p\/19q-codeleted anaplastic oligodendroglial tumors. Analysis of patients treated on the original protocol design","volume":"86","author":"Jaeckle","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.canrad.2025.104774_bib0950","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00066-020-01604-0","article-title":"Magnetic resonance imaging for brain stereotactic radiotherapy\u202f: A review of requirements and pitfalls","volume":"196","author":"Putz","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2025.104774_bib0955","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1016\/j.ijrobp.2011.10.021","article-title":"Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors","volume":"83","author":"Gondi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib0960","doi-asserted-by":"crossref","first-page":"103188","DOI":"10.1016\/j.critrevonc.2020.103188","article-title":"Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - Molecular, morphological and clinical features","volume":"157","author":"Le F\u00e8vre","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2025.104774_bib0965","doi-asserted-by":"crossref","first-page":"103230","DOI":"10.1016\/j.critrevonc.2021.103230","article-title":"Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers","volume":"159","author":"Le F\u00e8vre","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2025.104774_bib0970","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.prro.2013.11.003","article-title":"Target definition for malignant gliomas: no difference in radiation treatment volumes between 1.5 T and 3 T magnetic resonance imaging","volume":"4","author":"Guarnaschelli","year":"2014","journal-title":"Pract Radiat Oncol"},{"issue":"Suppl.","key":"10.1016\/j.canrad.2025.104774_bib0975","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.canrad.2016.07.032","article-title":"Delineation of organs at risk and dose constraints","volume":"20","author":"No\u00ebl","year":"2016","journal-title":"Cancer Radiother"},{"issue":"Suppl.","key":"10.1016\/j.canrad.2025.104774_bib0980","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.canrad.2016.07.008","article-title":"Guidelines for the radiotherapy of gliomas","volume":"20","author":"Feuvret","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104774_bib0985","doi-asserted-by":"crossref","unstructured":"Eber J., Bockel S., Antoni D., Khamphan C., No\u00ebl G., Le F\u00e8vre C. Delineation of organs at risk in radiotherapy and perspectives. Cancer Radiother 2025;29(7-8):104758. [In this issue].","DOI":"10.1016\/j.canrad.2025.104758"},{"issue":"1\u20132","key":"10.1016\/j.canrad.2025.104774_bib0990","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canrad.2021.11.001","article-title":"Organs at risk radiation dose constraints","volume":"26","author":"No\u00ebl","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104774_bib0995","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1523\/JNEUROSCI.3970-05.2006","article-title":"Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors","volume":"26","author":"Gil-Perotin","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.canrad.2025.104774_bib1000","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2013.12.011","article-title":"Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma","volume":"88","author":"Iuchi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib1005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ijrobp.2013.01.009","article-title":"Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis","volume":"86","author":"Lee","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104774_bib1010","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ijrobp.2014.07.027","article-title":"Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone","volume":"90","author":"Adeberg","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib1015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1754-9485.2011.02282.x","article-title":"Sparing of the hippocampus, limbic circuit and neural stem cell compartment during partial brain radiotherapy for glioma: a dosimetric feasibility study","volume":"55","author":"Marsh","year":"2011","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib1020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13014-021-01835-0","article-title":"Role of hippocampal location and radiation dose in glioblastoma patients with hippocampal atrophy","volume":"16","author":"Le F\u00e8vre","year":"2021","journal-title":"Radiat Oncol"},{"issue":"11","key":"10.1016\/j.canrad.2025.104774_bib1025","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/neuonc\/noaa076","article-title":"Hippocampal radiotherapy dose constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors","volume":"22","author":"Goda","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2025.104774_bib1030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.radonc.2022.10.016","article-title":"Dosimetric predictors of toxicity in a randomized study of short-course vs conventional radiotherapy for glioblastoma","volume":"177","author":"Yang","year":"2022","journal-title":"Radiother Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:15:48Z","timestamp":1768738548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":103,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1278321825001908"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104774","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy guidelines for gliomas: 2025 update","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}],"article-number":"104774"}}